Hi Red, A priority review voucher is a whole d
Post# of 30066
(Total Views: 673)
Posted On: 01/06/2018 8:27:33 AM
Hi Red,
A priority review voucher is a whole different story. If we had one of those, as you know, we could sell it for $150+ mil and set us up to finally get rid of the toxics and the “financial engineering.” Or we could use it to begin to fund trials, but let’s be honest, AMBS is not currently set up to move anything into large scale trials. My current company has 2 such vouchers and we are trying to figure out how best to utilize.
The quote from my post that you reference was taken directly from an article in Investopedia regarding orphan drugs.
Also, Dr. Urano’s trial of an old drug is significantly different than a company funding and launching large scale trials for a new indication for an old drug. Could it go there? Sure, I guess, but not likely. That’s just reality.
As to the cost of actually bringing Elto to market, the most recent estimates for cost of bringing a new drug to market is $2.5 billion.
https://www.bna.com/cost-bring-drug-b17179917704/
I had always used the $1 bil number, but apparently that is no longer correct.
The $6 million you referenced to get a trial done is low in my opinion and only a part of the process.
I don’t think that focusing solely on the pie in the sky what if’s for elto is really the only view that should be presented on this board. That’s why I throw in Some reality from my experience in Pharma business development. None of us know if we are right. I still stand by the thought that if Elto was such a diamond in the rough, we never would have gotten it for close to nothing. And again, I have never viewed Elto as being a valuable asset for AMBS. The market dictates the value of anything and thus far, my “worthless” description (while harsh) is based on current fact. Maybe that will someday change.
Have the more recent Elto studies been published in a reputable, peer to peer journal? No traction until they are.
Thanks, T
A priority review voucher is a whole different story. If we had one of those, as you know, we could sell it for $150+ mil and set us up to finally get rid of the toxics and the “financial engineering.” Or we could use it to begin to fund trials, but let’s be honest, AMBS is not currently set up to move anything into large scale trials. My current company has 2 such vouchers and we are trying to figure out how best to utilize.
The quote from my post that you reference was taken directly from an article in Investopedia regarding orphan drugs.
Also, Dr. Urano’s trial of an old drug is significantly different than a company funding and launching large scale trials for a new indication for an old drug. Could it go there? Sure, I guess, but not likely. That’s just reality.
As to the cost of actually bringing Elto to market, the most recent estimates for cost of bringing a new drug to market is $2.5 billion.
https://www.bna.com/cost-bring-drug-b17179917704/
I had always used the $1 bil number, but apparently that is no longer correct.
The $6 million you referenced to get a trial done is low in my opinion and only a part of the process.
I don’t think that focusing solely on the pie in the sky what if’s for elto is really the only view that should be presented on this board. That’s why I throw in Some reality from my experience in Pharma business development. None of us know if we are right. I still stand by the thought that if Elto was such a diamond in the rough, we never would have gotten it for close to nothing. And again, I have never viewed Elto as being a valuable asset for AMBS. The market dictates the value of anything and thus far, my “worthless” description (while harsh) is based on current fact. Maybe that will someday change.
Have the more recent Elto studies been published in a reputable, peer to peer journal? No traction until they are.
Thanks, T
(2)
(0)